« Canada is the No. 1 Country in the World, According to the 2021 Best Countries Report | Main | NASA Announces Winners of 2021 Human Exploration Rover Challenge (HERC). »
April 14, 2021
Sputnik V vaccine authorized in India.
• India has become the 60th country to approve Sputnik V.
• Sputnik V is one of only three vaccines registered in India.
• The Russian vaccine has been approved for use in countries with a total population of 3 billion.
Photo: SPUTNIK V VACCINE.
MOSCOW, April 13, 2021 — The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) announces that India’s Drug Controller General (DCGI) has approved the use of the Russian Sputnik V vaccine against coronavirus in the country. India has become the 60th country to support Sputnik V.
Sputnik V is one of only three coronavirus vaccines registered by India’s regulatory authorities.
India is the most populated country to register the Russian vaccine. The total population of 60 countries where Sputnik V is approved for use is 3 billion people, or about 40% of the global population.
India has registered the vaccine under the emergency use authorization procedure based on clinical trial results in Russia and positive data of additional Phase III local clinical trials in India conducted in partnership with Dr. Reddy’s Laboratories.
India is the leading production hub for Sputnik V. RDIF has reached agreements with the top pharmaceutical companies in the country (Gland Pharma, Hetero Biopharma, Panacea Biotec, Stelis Biopharma, Virchow Biotech) aimed at the production of more than 850 million doses per year.
Sputnik V ranks second among coronavirus vaccines globally regarding the number of approvals issued by government regulators.
Sputnik V has also been approved in Russia, Belarus, Argentina, Bolivia, Serbia, Algeria, Palestine, Venezuela, Paraguay, Turkmenistan, Hungary, UAE, Iran, Republic of Guinea, Tunisia, Armenia, Mexico, Nicaragua, Republika Srpska (an entity of Bosnia and Herzegovina), Lebanon, Myanmar, Pakistan, Mongolia, Bahrain, Montenegro, Saint Vincent and the Grenadines, Kazakhstan, Uzbekistan, Gabon, San-Marino, Ghana, Syria, Kyrgyzstan, Guyana, Egypt, Honduras, Guatemala, Moldova, Slovakia, Angola, Republic of the Congo, Djibouti, Sri Lanka, Laos, Iraq, North Macedonia, Kenya, Morocco, Jordan, Namibia, Azerbaijan, Philippines, Cameroon, Seychelles, Mauritius, Vietnam, Antigua and Barbuda, Mali, and Panama.
Kirill Dmitriev, CEO of the Russian Direct Investment Fund, said:
“We appreciate the decision of India’s regulatory bodies to grant authorization for Sputnik V. Approval of the vaccine is a significant milestone as Russia and India have been developing extensive cooperation on clinical trials of Sputnik V in India and its local production.
“The Russian vaccine has efficacy of 91.6% and provides complete protection against severe cases of COVID-19 as demonstrated by the data published in one of the leading medical journals, The Lancet.
“India is a vaccine-manufacturing hub and our strategic partner for the production of Sputnik V. We have created partnerships with several Indian leading pharmaceutical companies for Sputnik V production, which will provide for both vaccinations of the population in India and global distribution. Over 850 million doses of Sputnik V are going to be produced in India annually sufficient to vaccinate more than 425 million people around the world.”
• According to RDIF, Sputnik V has many key advantages:
Efficacy of Sputnik V is 91.6%, as confirmed by the data published in the Lancet, one of the world’s oldest and most respected medical journals; it is one of only three vaccines in the world with an efficacy of over 90%; Sputnik V provides complete protection against severe cases of COVID-19.
The Sputnik V vaccine is based on a proven and well-studied platform of human adenoviral vectors, which cause the common cold and have been around for thousands of years.
Sputnik V uses two different vectors for the two shots in vaccination, providing immunity with a longer duration than vaccines using the exact delivery mechanism for both shots.
More than 250 clinical studies have proved the safety, efficacy, and lack of adverse long-term effects of adenoviral vaccines over two decades. There are no strong allergies caused by Sputnik V.
The storage temperature of Sputnik V at +2+8 C means that we can store it in a conventional refrigerator without any need to invest in additional cold-chain infrastructure.
Sputnik V’s price is less than $10 per shot, making it affordable worldwide.
Russian Direct Investment Fund (RDIF) is Russia’s sovereign wealth fund established in 2011 to make equity co-investments, primarily in Russia, alongside reputable international financial and strategic investors.
Source: Russian Direct Investment Fund (RDIF)
|GlobalGiants.Com|
Edited & Posted by the Editor | 11:13 AM | Link to this Post
